Literature DB >> 24698505

High expression of zinc-binding protein-89 predicts decreased survival in esophageal squamous cell cancer.

Shu-Mei Yan1, Hui-Ni Wu2, Fan He3, Xiao-peng Hu4, Zhi-yi Zhang1, Ma-Yan Huang1, Xiao Wu5, Chun-yu Huang6, Yong Li7.   

Abstract

BACKGROUND: Zinc-binding protein-89 (ZBP-89), a Krüppel-type four-zinc finger transcription factor, is associated with many cellular functions, including cell growth, differentiation, and apoptosis. It has been reported to be involved in several human cancers. However, ZBP-89 expression pattern and its clinical significance have not yet been investigated in esophageal squamous cell cancer.
METHODS: In this study, immunostaining was performed to detect ZBP-89 expression in esophageal squamous cell cancer, and then the correlations between ZBP-89 expression and both clinicopathologic variables and overall survival were analyzed.
RESULTS: Compared with adjacent normal tissues, ZBP-89 expression was significantly upregulated in esophageal squamous cell cancer tissues. Increased ZBP-89 expression was associated with N category (p = 0.009) and TNM stage (p = 0.023). Patients with high expression of ZBP-89 demonstrated shortened overall survival compared with those with low expression of ZBP-89 (mean overall survival, 56.961 months versus 76.029 months; p < 0.001). Multivariate Cox regression analysis indicated that ZBP-89 expression had a significant, independent predictive value for survival of esophageal squamous cell cancer (relative risk, 1.581; p = 0.024).
CONCLUSIONS: Our data show that increased expression of ZBP-89 is associated with poor prognosis for esophageal squamous cell cancer patients and may act as a novel, useful, and independent prognostic indicator for esophageal squamous cell cancer. Further studies are warranted.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24698505     DOI: 10.1016/j.athoracsur.2014.01.058

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Transcription Factor ZBP-89 Drives a Feedforward Loop of β-Catenin Expression in Colorectal Cancer.

Authors:  Bryan E Essien; Sinju Sundaresan; Ramon Ocadiz-Ruiz; Aaron Chavis; Amy C Tsao; Arthur J Tessier; Michael M Hayes; Amanda Photenhauer; Milena Saqui-Salces; Anthony J Kang; Yatrik M Shah; Balazs Győrffy; Juanita L Merchant
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

2.  Targeting Zfp148 activates p53 and reduces tumor initiation in the gut.

Authors:  Anna Nilton; Volkan I Sayin; Zhiyuan V Zou; Sama I Sayin; Cecilia Bondjers; Nadia Gul; Pia Agren; Per Fogelstrand; Ola Nilsson; Martin O Bergo; Per Lindahl
Journal:  Oncotarget       Date:  2016-08-30

3.  Peritumoral overexpression of ZBP-89 is associated with unfavorable disease-free survival rates in patients with hepatocellular carcinoma following hepatectomy.

Authors:  Qiu-Shuang Wang; Chen Chen; Jing Zhan; Xie-Fan Fang; George G Chen; Sheng-Li Yang; Ren-Wang Chen; Fan Tong; Jian-Li Hu
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

4.  A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer.

Authors:  Mijeong Kim; Manjot Singh; Bum-Kyu Lee; Moira Hibbs; Kirsty Richardson; Lesley Ellies; Larissa Wintle; Lisa M Stuart; Jenny Y Wang; Dominic C Voon; Pilar Blancafort; Jianlong Wang; Jonghwan Kim; Peter J Leedman; Andrew J Woo
Journal:  Oncogenesis       Date:  2022-10-07       Impact factor: 6.524

5.  Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.

Authors:  Shumei Yan; Fan He; Bei Gao; Huini Wu; Mei Li; Liyun Huang; Jianzhong Liang; Qiuliang Wu; Yong Li
Journal:  J Cancer       Date:  2016-03-19       Impact factor: 4.207

6.  INHBA upregulation correlates with poorer prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Shanshan Lyu; Chao Jiang; Rui Xu; Yuhua Huang; Shumei Yan
Journal:  Cancer Manag Res       Date:  2018-06-18       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.